Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 908 Devices Inc.MASS · Entity 5564 | Director | June 10, 2026 | June 12, 2026 |
| REPLIGEN CORPRGEN · Entity 486 | Director | March 02, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
908 Devices Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,168 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Exercise / conversion · Acquired 14,083 · Balance 44,168 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Exercise / conversion · Disposed 14,083 · Balance 0 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F2: The RSUs became fully vested on June 10, 2026, the day prior to the 2026 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 13,656 |
Reported balance
After 2026-06-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-11 · Grant · Acquired 13,656 · Balance 13,656 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F3: The RSUs become fully vested on June 11, 2027 or the day prior to the 2027 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. |
| Stock Option (option to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.22 · Expires 2036-06-10 | Direct | 6,209 |
Reported balance
After 2026-06-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-11 · Grant · Acquired 6,209 · Balance 6,209 F4: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following June 11, 2026, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested.
F2: The RSUs became fully vested on June 10, 2026, the day prior to the 2026 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date.
F3: The RSUs become fully vested on June 11, 2027 or the day prior to the 2027 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date.
F4: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following June 11, 2026, subject to the reporting person's continued service through the applicable vesting date.
REPLIGEN CORP
Report date March 02, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 89,062 |
Reported balance
After 2026-03-02 transaction · row 1
1 source rowRow 1 · 2026-03-02 · Tax withholding · Disposed 9,897 · Balance 89,062 F1: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 1
1 source rowRow 1 · 2026-10-06 · Disposition to issuer · Disposed 15,046 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 9, 2026 01:58 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Disposition to issuerCommon Stock | 15,046 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-418319 · ownership.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 20:48 UTC | 908 Devices Inc. MASS · Entity 5564 | GrantStock Option (option to buy) · Derivative | 6,209 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001606030-26-000002 · form4-06122026_080639.xml · derivative · entry 4 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,209 Underlying: Common Stock · 6,209 shares Expires 2036-06-10 F4 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following June 11, 2026, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 20:48 UTC | 908 Devices Inc. MASS · Entity 5564 | GrantRestricted Stock Units · Derivative | 13,656 | $0.00 | $0.00 |
DisclosureSEC source: 0001606030-26-000002 · form4-06122026_080639.xml · derivative · entry 3 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,656 Underlying: Common Stock · 13,656 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F3 · derivative.exercise_date: The RSUs become fully vested on June 11, 2027 or the day prior to the 2027 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. F3 · derivative.expiration_date: The RSUs become fully vested on June 11, 2027 or the day prior to the 2027 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:48 UTC | 908 Devices Inc. MASS · Entity 5564 | Exercise / conversionRestricted Stock Units · Derivative | 14,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001606030-26-000002 · form4-06122026_080639.xml · derivative · entry 2 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,083 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F2 · derivative.exercise_date: The RSUs became fully vested on June 10, 2026, the day prior to the 2026 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date. F2 · derivative.expiration_date: The RSUs became fully vested on June 10, 2026, the day prior to the 2026 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:48 UTC | 908 Devices Inc. MASS · Entity 5564 | Exercise / conversionCommon Stock | 14,083 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001606030-26-000002 · form4-06122026_080639.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 18:38 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 9,897 | $124.97 | $1,236,828.09 |
DisclosureSEC source: 0001193125-26-087591 · ownership.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,062 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:56 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 8,170 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-012478 · wk-form4_1772146558.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,046 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan and fully vests on the first anniversary of the vesting date of January 2, 2026 Read SEC document |
| December 04, 2025 Filed Dec 8, 2025 21:30 UTC | REPLIGEN CORP RGEN · Entity 486 | OtherCommon Stock | 2,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-311290 · ownership.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,959 F1 · kind: Represents a transfer of shares for which the Reporting Person is a joint tenant with right of survivorship. F1 · price: Represents a transfer of shares for which the Reporting Person is a joint tenant with right of survivorship. F1 · ownership.direct: Represents a transfer of shares for which the Reporting Person is a joint tenant with right of survivorship. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:30 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,952 | $0.00 Strike: $33.87 | $0.00 |
DisclosureSEC source: 0001193125-25-283092 · ownership.xml · derivative · entry 9 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,760 Underlying: Common Stock · 2,952 shares Expires 2028-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: 14,760 of the shares underlying this option have vested. The remaining shares vest as follows: 2,952 shares on March 1, 2026, and 2,952 shares on March 1, 2027. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:30 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 2,952 | $33.87 | $99,984.24 |
DisclosureSEC source: 0001193125-25-283092 · ownership.xml · nonDerivative · entry 8 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:30 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,956 | $157.11 | $307,307.16 |
DisclosureSEC source: 0001193125-25-283092 · ownership.xml · nonDerivative · entry 7 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,743 F7 · price: $157.11 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.90 to $157.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:30 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 5,737 | $156.22 | $896,234.14 |
DisclosureSEC source: 0001193125-25-283092 · ownership.xml · nonDerivative · entry 6 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,699 F6 · price: $156.22 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.79 to $156.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:30 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 3,000 | $155.45 | $466,350.00 |
DisclosureSEC source: 0001193125-25-283092 · ownership.xml · nonDerivative · entry 5 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,436 F5 · price: $155.45 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.78 to $155.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:30 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 2,500 | $154.32 | $385,800.00 |
DisclosureSEC source: 0001193125-25-283092 · ownership.xml · nonDerivative · entry 4 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,436 F4 · price: $154.32 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.66 to $154.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:30 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 2,923 | $153.14 | $447,628.22 |
DisclosureSEC source: 0001193125-25-283092 · ownership.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,936 F3 · price: $153.14 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.64 to $153.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:30 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 2,100 | $152.17 | $319,557.00 |
DisclosureSEC source: 0001193125-25-283092 · ownership.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,859 F2 · price: $152.17 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.57 to $152.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:30 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,784 | $151.01 | $269,401.84 |
DisclosureSEC source: 0001193125-25-283092 · ownership.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,959 F1 · price: $151.01 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.53 to $151.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 21:30 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $33.87 | $0.00 |
DisclosureSEC source: 0001193125-25-280266 · ownership.xml · derivative · entry 7 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,344 Underlying: Common Stock · 25,000 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 207,344 of the shares underlying this option have vested. The remaining shares vest as follows: 28,777 shares on March 1, 2026, and 28,778 shares on March 1, 2027. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 21:30 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 464 | $158.51 | $73,548.64 |
DisclosureSEC source: 0001193125-25-280266 · ownership.xml · nonDerivative · entry 6 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,743 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. F6 · price: $158.51 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.43 to $158.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 21:30 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 11,096 | $158.01 | $1,753,278.96 |
DisclosureSEC source: 0001193125-25-280266 · ownership.xml · nonDerivative · entry 5 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,207 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. F5 · price: $158.01 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.41 to $158.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 21:30 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 4,959 | $156.65 | $776,827.35 |
DisclosureSEC source: 0001193125-25-280266 · ownership.xml · nonDerivative · entry 4 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,303 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. F4 · price: $156.65 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.31 to $157.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 21:30 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 4,740 | $155.85 | $738,729.00 |
DisclosureSEC source: 0001193125-25-280266 · ownership.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,262 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. F3 · price: $155.85 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.28 to $156.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 21:30 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 3,741 | $154.92 | $579,555.72 |
DisclosureSEC source: 0001193125-25-280266 · ownership.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,002 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. F2 · price: $154.92 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.26 to $155.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 21:30 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 25,000 | $33.87 | $846,750.00 |
DisclosureSEC source: 0001193125-25-280266 · ownership.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,743 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 18:55 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $33.87 | $0.00 |
DisclosureSEC source: 0001193125-25-201224 · ownership.xml · derivative · entry 8 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,344 Underlying: Common Stock · 20,000 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 207,344 of the shares underlying this option have vested. The remaining shares vest as follows: 28,777 shares on March 1, 2026, and 28,778 shares on March 1, 2027. Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 18:55 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 2,179 | $122.23 | $266,339.17 |
DisclosureSEC source: 0001193125-25-201224 · ownership.xml · nonDerivative · entry 7 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,743 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. F6 · price: $122.23 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.92 to $122.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 18:55 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 7,584 | $121.42 | $920,849.28 |
DisclosureSEC source: 0001193125-25-201224 · ownership.xml · nonDerivative · entry 6 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,922 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. F5 · price: $121.42 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.86 to $121.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 18:55 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 14,882 | $120.19 | $1,788,667.58 |
DisclosureSEC source: 0001193125-25-201224 · ownership.xml · nonDerivative · entry 5 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,506 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. F4 · price: $120.19 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.85 to $120.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 18:55 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 3,262 | $119.64 | $390,265.68 |
DisclosureSEC source: 0001193125-25-201224 · ownership.xml · nonDerivative · entry 4 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,388 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. F3 · price: $119.64 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.83 to $119.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 18:55 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,108 | $118.32 | $131,098.56 |
DisclosureSEC source: 0001193125-25-201224 · ownership.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,650 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. F2 · price: $118.32 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.80 to $118.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 18:55 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 96 | $116.34 | $11,168.64 |
DisclosureSEC source: 0001193125-25-201224 · ownership.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,758 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 18:55 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 20,000 | $33.87 | $677,400.00 |
DisclosureSEC source: 0001193125-25-201224 · ownership.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 20:21 UTC | 908 Devices Inc. MASS · Entity 5564 | GrantStock Option (option to buy) · Derivative | 6,516 | $0.00 Strike: $7.19 | $0.00 |
DisclosureSEC source: 0001562180-25-004809 · primarydocument.xml · derivative · entry 4 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,516 Underlying: Common Stock · 6,516 shares Expires 2035-06-11 F5 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following June 12, 2025, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 20:21 UTC | 908 Devices Inc. MASS · Entity 5564 | GrantRestricted Stock Units · Derivative | 14,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-004809 · primarydocument.xml · derivative · entry 3 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,083 Underlying: Common Stock · 14,083 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F4 · derivative.exercise_date: The RSUs become fully vested on June 12, 2026 or the day prior to the 2026 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. F4 · derivative.expiration_date: The RSUs become fully vested on June 12, 2026 or the day prior to the 2026 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:21 UTC | 908 Devices Inc. MASS · Entity 5564 | Exercise / conversionRestricted Stock Units · Derivative | 11,364 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-004809 · primarydocument.xml · derivative · entry 2 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,364 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. This transaction represents the settlement of RSUs in shares of Common Stock on their scheduled vesting date. F2 · derivative.exercise_date: The RSUs became fully vested on June 11, 2025, the day prior to the 2025 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date. F2 · derivative.expiration_date: The RSUs became fully vested on June 11, 2025, the day prior to the 2025 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:21 UTC | 908 Devices Inc. MASS · Entity 5564 | Exercise / conversionCommon Stock | 11,364 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-25-004809 · primarydocument.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. This transaction represents the settlement of RSUs in shares of Common Stock on their scheduled vesting date. Read SEC document |
| May 15, 2025 Filed May 16, 2025 19:02 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 7 | $127.00 | $889.00 |
DisclosureSEC source: 0000950170-25-073387 · ownership.xml · nonDerivative · entry 5 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,854 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. Read SEC document |
| May 15, 2025 Filed May 16, 2025 19:02 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 268 | $125.20 | $33,553.60 |
DisclosureSEC source: 0000950170-25-073387 · ownership.xml · nonDerivative · entry 4 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,861 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. F5 · price: $125.20 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.06 to $126.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 15, 2025 Filed May 16, 2025 19:02 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 6,533 | $124.34 | $812,313.22 |
DisclosureSEC source: 0000950170-25-073387 · ownership.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,129 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. F4 · price: $124.34 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.05 to $125.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 15, 2025 Filed May 16, 2025 19:02 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 17,596 | $123.57 | $2,174,337.72 |
DisclosureSEC source: 0000950170-25-073387 · ownership.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,662 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. F3 · price: $123.57 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.04 to $124.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 15, 2025 Filed May 16, 2025 19:02 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 2,043 | $122.66 | $250,594.38 |
DisclosureSEC source: 0000950170-25-073387 · ownership.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,258 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. F2 · price: $122.66 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.03 to $123.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 23:09 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 6,876 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-014190 · wk-form4_1742512151.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,876 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the measurement date of 01-02-2025. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:21 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 21,756 | $0.00 Strike: $59.52 | $0.00 |
DisclosureSEC source: 0000950170-25-042026 · ownership.xml · derivative · entry 10 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,756 shares Expires 2029-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:21 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $33.87 | $0.00 |
DisclosureSEC source: 0000950170-25-042026 · ownership.xml · derivative · entry 9 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 202,344 Underlying: Common Stock · 5,000 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 207,344 of the shares underlying this option have vested. The remaining shares vest as follows: 28,777 shares on March 1, 2026, and 28,778 shares on March 1, 2027. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:21 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 2,283 | $153.70 | $350,897.10 |
DisclosureSEC source: 0000950170-25-042026 · ownership.xml · nonDerivative · entry 8 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,301 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. F6 · price: $153.70 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.55 to $153.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:21 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 15,619 | $152.82 | $2,386,895.58 |
DisclosureSEC source: 0000950170-25-042026 · ownership.xml · nonDerivative · entry 7 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,584 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. F5 · price: $152.82 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.39 to $153.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:21 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 6,176 | $151.96 | $938,504.96 |
DisclosureSEC source: 0000950170-25-042026 · ownership.xml · nonDerivative · entry 6 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,203 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. F4 · price: $151.96 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.43 to $152.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:21 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 2,518 | $151.09 | $380,444.62 |
DisclosureSEC source: 0000950170-25-042026 · ownership.xml · nonDerivative · entry 5 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 160,379 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. F3 · price: $151.09 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.42 to $151.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:21 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 100 | $150.38 | $15,038.00 |
DisclosureSEC source: 0000950170-25-042026 · ownership.xml · nonDerivative · entry 4 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,897 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:21 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 60 | $148.05 | $8,883.00 |
DisclosureSEC source: 0000950170-25-042026 · ownership.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,997 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 9, 2024. F2 · price: $148.05 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.01 to $148.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.